NTRA (Natera) Total Long-Term Liabilities: $282 Mil (As of Mar. 2026)


NTRA Natera Inc NTRA
80 GF Score
Price $258.97
GF Value $202.05
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Natera Total Long-Term Liabilities?

Natera NTRA +10.31% 80 Total Long-Term Liabilities is $282 Mil as of Mar. 2026. GuruFocus rates NTRA with a GF Score™ of 80/100 and a GF Value™ of $202.05 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Natera's Total Long-Term Liabilities for the quarter that ended in Mar. 2026 was $282 Mil.

Natera Total Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Natera's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natera Total Long-Term Liabilities Chart

Natera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 364.23 378.23 369.10 121.27 244.70

Natera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.01 126.05 127.28 244.70 282.12
NTRA
80GF Score
Natera Inc NTRA
Total Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natera Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

What does a Total Long-Term Liabilities of $282 Mil mean?
Natera (NTRA) has a Total Long-Term Liabilities of $282 Mil as of Mar. 2026. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Natera and its competitors.
Is Natera's Total Long-Term Liabilities too high?
Natera's current Total Long-Term Liabilities is $282 Mil. Overall, Natera has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Total Long-Term Liabilities compare to IQV and WAT?
Natera's Total Long-Term Liabilities of $282 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Total Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Liabilities mean?
A high Total Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Natera and its competitors. Natera's current Total Long-Term Liabilities is $282 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (NTRA) is currently considered Modestly Overvalued. The stock's GF Value™ is $202.05, compared to a current price of $258.97 — trading 28.2% above its estimated fair value. The current Total Long-Term Liabilities is $282 Mil. Natera's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Liabilities calculated?
Total Long-Term Liabilities is calculated from a company's financial statements. For Natera (NTRA), the current Total Long-Term Liabilities is $282 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natera (NTRA) Overvalued in 2026?

Based on GuruFocus' analysis, Natera stock appears to be overvalued. The current stock price of $258.97 is trading 28.2% above its estimated GF Value™ of $202.05. GuruFocus considers Natera to be Modestly Overvalued.

Key valuation signals for NTRA:

  • Total Long-Term Liabilities: $282 Mil
  • GF Value™: $202.05 vs. price of $258.97 (28.2% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natera Business Description

Other Exchanges NTRA:Mexico45E:Germany
Address 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
80GF Score

Get the complete analysis for NTRA

Total Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$258.97
Price
$202.05
GF Value